Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for neuroprotection after out-of-hospital cardiac arrest
2013-004311-45Phase 3Completed
- Sponsor
- Rigshospitalet
- Start
- Feb 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac arrest (SCA) and hypoxic-ischemic encephalopathy (HIE) comparing Exenatide with Placebo (2 arms). Primary endpoints: Feasibility of rapid study drug initiation and Area under the neuron-specific enolase curve. Started Feb 2014; status: completed.
02
Drugs
exenatide
03
Conditions
cardiac arrest (SCA)hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on 2013-004311-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004311-45.